Alnylam Pharmaceuticals: Dawn score and attention ranking
Alnylam Pharmaceuticals scores 42 out of 100 on the Dawn Index, built from 4 signals. It ranks #7 of 9 in Health Care (Nasdaq-100), #80 of 91 in Nasdaq-100.
What drives the Alnylam Pharmaceuticals Dawn score?
| Signal | Weight | Score (0 to 100) |
|---|---|---|
| Search scale | 20% | 38 |
| Search momentum | 20% | 34 |
| Site scale | 15% | 37 |
| Site momentum | 10% | 64 |
How does Alnylam Pharmaceuticals compare in Health Care (Nasdaq-100)?
| Rank | Brand | Dawn score |
|---|---|---|
| 1 | Dexcom | 56 |
| 2 | Gilead Sciences | 50 |
| 3 | Intuitive Surgical | 49 |
| 4 | GE HealthCare | 47 |
| 5 | Idexx Laboratories | 47 |
| 6 | Vertex Pharmaceuticals | 46 |
| 7 | Alnylam Pharmaceuticals | 42 |
| 8 | Amgen | 41 |
Where do the numbers come from?
Search figures are Google search estimates for the brand and its products. Site figures are third-party traffic estimates. A Dawn score measures attention, not revenue.